Healthcare provider profile · identity verified

Ramon Sy, MD

Internal Medicine · SAN YSIDRO, CA · NPI 1982617403

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	655	217
Amlodipine Besylate	Amlodipine Besylate	496	155
Metformin Hcl	Metformin Hcl	413	129
Lisinopril	Lisinopril	308	101
Losartan Potassium	Losartan Potassium	282	91
Jardiance	Empagliflozin	254	64
Gabapentin	Gabapentin	240	85
Levothyroxine Sodium	Levothyroxine Sodium	168	50
Fluticasone Propionate	Fluticasone Propionate	156	60
Famotidine	Famotidine	149	49
Omeprazole	Omeprazole	149	57
Metoprolol Tartrate	Metoprolol Tartrate	142	47
Hydrochlorothiazide	Hydrochlorothiazide	138	49
Trulicity	Dulaglutide	134	28
Pantoprazole Sodium	Pantoprazole Sodium	131	53
Alendronate Sodium	Alendronate Sodium	130	43
Diclofenac Sodium	Diclofenac Sodium	128	44
Tamsulosin Hcl	Tamsulosin Hcl	110	38
Tradjenta	Linagliptin	90	26
Glipizide	Glipizide	88	31
Trazodone Hcl	Trazodone Hcl	85	29
Chlorthalidone	Chlorthalidone	74	23
Sertraline Hcl	Sertraline Hcl	74	19
Albuterol Sulfate Hfa	Albuterol Sulfate	71	23
Metoprolol Succinate	Metoprolol Succinate	71	26
Pravastatin Sodium	Pravastatin Sodium	68	23
Carvedilol	Carvedilol	64	21
Simvastatin	Simvastatin	64	16
Atenolol	Atenolol	63	19
Furosemide	Furosemide	60	20
Nifedipine Er	Nifedipine	60	23
Eliquis	Apixaban	53	12
Triamcinolone Acetonide	Triamcinolone Acetonide	53	23
Benazepril Hcl	Benazepril Hcl	48	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	46	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	46	18
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	12
Ketoconazole	Ketoconazole	45	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	14
Lantus	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Januvia	Sitagliptin Phosphate	39	16
Allopurinol	Allopurinol	35	12
Finasteride	Finasteride	35	14
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Meclizine Hcl	Meclizine Hcl	32	15
Valsartan	Valsartan	32	12
Glipizide Er	Glipizide	31	11
Ozempic	Semaglutide	31	suppressed
Sucralfate	Sucralfate	28	suppressed
Ibuprofen	Ibuprofen	27	suppressed
Potassium Chloride	Potassium Chloride	26	12
Glimepiride	Glimepiride	23	suppressed
Spironolactone	Spironolactone	22	suppressed
Pregabalin	Pregabalin	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Meloxicam	Meloxicam	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Bumetanide	Bumetanide	15	suppressed
Dutasteride	Dutasteride	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Levemir	Insulin Detemir	14	suppressed
Linzess	Linaclotide	14	suppressed
Naproxen	Naproxen	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Tresiba Flextouch U-200	Insulin Degludec	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Baclofen	Baclofen	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Semglee (Yfgn)	Insulin Glargine-Yfgn	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Prolia	Denosumab	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error